Ongoing legal warnings on the uncertainty surrounding CBD commerce may be on their deathbead–at least in the Golden State. Prospects for CBD sales are all-time sunny after the Sacramento Assembly’s Business and Professions, Health, and Appropriations committees unanimously passed AB 218, which removes all sales restrictions from all products containing the ingredient.
Yet, legal advisors continue to remind vendors that “virtually all products containing CBD are regulated by the FDA.”
Green Camp/Cannabis Industry Journal
- “It is highly unusual that CBD has been able to proliferate in the marketplace given the FDA’s technical legal position on it,” writes Jonathan Shandler. And even though CBD can seem ubiquitous here, Shandler speaks the unvarnished truth. While operators have been able to function, reminders of the drug’s netherworld status remain. Last month, websites peddling unproven claims received letters from the department.
- The FDA will hold a public hearing on May 31. The idea is for the hearing to generate feedback from interested parties so that the department can clarify federal industry standards.